New crown oral drugs and a variety of rare disease drugs passed the 2022 medical insurance catalogue adjustment review

From September 6 to 12, 2022, our bureau announced to the public the "List of Declared Drugs Approved by the Preliminary Form Examination of the Adjustment of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue in 2022"
.
According to the feedback from all parties, our bureau has reviewed and revised the results of relevant drugs in accordance with the procedures, and now officially publishes the "List of Declared Drugs Approved by the Form Review of the Adjustment of the Drug Catalogue of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance in 2022"
.
In the next step, our bureau will organize expert review and other work
in accordance with the requirements of the "Interim Measures for the Administration of Drugs in Basic Medical Insurance" and the "2022 National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalogue Adjustment Work Plan".
Relevant enterprises are invited to pay attention to the national medical insurance service platform "2022 National Medical Insurance Drug Catalogue Adjustment Declaration Module" to obtain relevant review, negotiation, agreement and other information
of the National Medical Insurance Bureau in a timely manner.
Attachment: List of declared drugs that have passed the formal examination in 2022 National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue Adjustment National Medical Security Bureau September 17, 2022 The list of declared drugs for enterprises in 2022 National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue Adjustment Passed the Form Review 2022 National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance The list of drugs adjusts the list of declared drugs that have passed the formal examination